Good Results for Q.E and Year Ending - IOL Chemicals & Pharmaceuticals Ltd

BSE: 524164 NSE:

Below is snapshot of Q4 FY25 Financial Performance for IOL Chemicals & Pharmaceuticals Ltd a) Revenue from Operations = Rs 527.8 Cr Up 4.7% b) EBITDA = Rs 67.5 Cr Up 17.1% c) Profit After Tax = Rs 31.6 Cr Up 12.2% Q4 FY25 Operational Highlights are as below (i) Successfully Commissioned Unit-11 for Paracetamol at the Barnala facility with an annual capacity of 10,800 MTPA; Rs 155.51 crore investment fully funded through internal accruals. (ii) Expanded Clopidogrel Bisulphate capacity from 180 MTPA to 240 MTPA at Unit-5 with an investment of Rs 7.87 crore, financed through internal funds. (iiI) Received EDQM Certification of Suitability (CEPs) for Mesalazine and Quetiapine Fumarate, enabling exports to Europe and other CEP-compliant markets. (iv) Secured approval from China’s National Medical Products Administration (NMPA) to export Ibuprofen, marking entry into one of the world’s largest pharmaceutical markets (v) Acquired 101 acres along the Chandigarh-Bathinda Highway for future expansion; regulatory and environmental clearances currently in progress.